Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Clayton
Clinical trial register · Australia

Clinical Trials in Clayton, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Australia and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3335 matching records held by the registry are in this view. Synced 30 Sep 2026, 03:17 UTC
3335
Studies in scope
all four open statuses
1809
Recruiting now
open to new participants
761
Lead sponsors
across recruiting studies
Top sites
Melbourne 37 Clayton 21 Murdoch 19 Camperdown 17 Heidelberg 16
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca27 Merck Sharp & Dohme LLC22 Janssen Research & Development, LLC21 AbbVie19 Novartis Pharmaceuticals18 Clear sponsor filter
Site location
Melbourne37 Clayton21 Murdoch19 Camperdown17 Heidelberg16
All 73 locations
Target enrolment
to

Trials with a site in Clayton

21 of 3335 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Australia
Start
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856Colitis, Ulcerative
DrugsJNJ-78934804·Tremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
644
Adelaide, Camperdown, Clayton, East Melbourne, Kurralta Park, Murdoch, New Lambton Heights, South Brisbane
2026-05-23
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843Crohn Disease
DrugsJNJ-78934804·Tremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
460
Adelaide, Camperdown, Clayton, East Melbourne, Kurralta Park, New Lambton Heights, South Brisbane
2026-05-22
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511Multiple Myeloma
DrugsRamantamig·Teclistamab
Janssen Research & Development, LLC
Phase 3
400
Box Hill, Brisbane, Clayton, Fitzroy, Melbourne, Murdoch, Nedlands, Southport
2026-02-04
Recruiting
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
NCT07308132Lymphoma, Non-Hodgkin
DrugsJNJ-87801493·Loncastuximab Tesirine·Polatuzumab Vedotin·Vincristine
Janssen Research & Development, LLC
Phase 1
340
Clayton, Melbourne, North Ryde, Randwick
2026-01-20
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399Squamous Cell Carcinoma of Head and Neck
DrugsAmivantamab·Cisplatin·Carboplatin·Pembrolizumab
Janssen Research & Development, LLC
Phase 3
500
Clayton, Liverpool, Melbourne, Murdoch, St Leonards
2025-12-03
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722Crohn Disease
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 2/3
1,092
Clayton, Concord, Fitzroy, Murdoch, New Lambton Heights, South Brisbane
2025-10-03
Recruiting
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
NCT07149857Multiple Myeloma
DrugsCilta-cel·Fludarabine·Cyclophosphamide
Janssen Research & Development, LLC
Phase 2
60
Camperdown, Clayton, Heidelberg, Murdoch, Woolloongabba
2025-10-03
Recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748Colitis, Ulcerative
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
882
Clayton, Concord, Fitzroy, Murdoch, New Lambton Heights, Parkville, South Brisbane
2025-10-01
Active, closed
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226Plaque Psoriasis
DrugsIcotrokinra·Ustekinumab
Janssen Research & Development, LLC
Phase 3
752
Clayton, Coorparoo, Greenslopes, Kogarah, Melbourne, Mitcham, Westmead
2025-04-15
Recruiting
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
NCT06768489Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
DrugsRamantamig·Pomalidomide·Daratumumab·Lenalidomide
Janssen Research & Development, LLC
Phase 1
276
Clayton, Fitzroy, Melbourne, Waratah, Wollongong
2024-12-04
Active, closed
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
NCT06220604Plaque Psoriasis
DrugsIcotrokinra·Deucravacitinib
Janssen Research & Development, LLC
Phase 3
731
Benowa, Clayton, Kogarah, Melbourne, Mitcham, Parkville
2024-03-09
Active, closed
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
NCT05784441Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC
Phase 1
21
Camperdown, Clayton, Heidelberg, Herston, Westmead
2023-11-06
Active, closed
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034Ischemic Stroke; Ischemic Attack, Transient
DrugMilvexian
Janssen Research & Development, LLC
Phase 3
12,523
Adelaide, Box Hill, Campbelltown, Camperdown, Clayton, Fitzroy, Heidelberg, Herston
2023-02-15
Active, closed
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
NCT05453903Leukemia, Myeloid, Acute
DrugsBleximenib·Idarubicin·Daunorubicin·Cytarabine
Janssen Research & Development, LLC
Phase 1
196
Clayton, Melbourne, Westmead
2022-10-04
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484Colitis, Ulcerative
DrugsJNJ-78934804·Golimumab·Guselkumab
Janssen Research & Development, LLC
Phase 2
577
Box Hill, Camperdown, Clayton, Concord, Footscray, Maroochydore, Murdoch, North Terrace
2022-09-19
Active, closed
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05528510Colitis, Ulcerative
DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3
Janssen Research & Development, LLC
Phase 3
418
Adelaide, Camperdown, Clayton, Herston, Murdoch, Parkville, South Brisbane, Woodville South
2022-09-13
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471Crohn's Disease
DrugsJNJ-78934804·Golimumab·Guselkumab
Janssen Research & Development, LLC
Phase 2
703
Adelaide, Box Hill, Clayton, Footscray, Melbourne, Newtown, North Terrace, Parkville
2022-07-22
Active, closed
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
NCT05197049Crohn Disease
DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3
Janssen Research & Development, LLC
Phase 3
350
Clayton, North Mackay
2022-01-19
Recruiting
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
NCT04811560Acute Leukemia
DrugBleximenib
Janssen Research & Development, LLC
Phase 1/2
420
Clayton, Perth, Southport
2021-05-19
Active, closed
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04033445Ulcerative Colitis
DrugGuselkumab
Janssen Research & Development, LLC
Phase 2/3
1,064
Camberwell, Clayton, Footscray, Murdoch, Perth, South Brisbane, Subiaco, Woolloongabba
2019-09-26
Active, closed
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411Crohn's Disease
DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3·Ustekinumab
Janssen Research & Development, LLC
Phase 2/3
1,409
Adelaide, Clayton, Concord, Heidelberg, Nedlands, North Terrace, Parkville, Penrith
2018-04-13
Rows per page Showing 1–21 of 21
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Australian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 2 October 2026. https://priyalifescience.com/clinical-trials-australia/city/clayton

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Australia and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,335 studies in total at the last sync on 30 Sep 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 21 of those studies with a site in Clayton that also match the filters currently applied.

How many clinical trials are recruiting in Clayton?

10 of the 21 studies on this page are recruiting new participants as of the 30 Sep 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 11 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Clayton), 21 studies
PhaseStudiesRecruitingShare
Phase 310547.6%
Phase 14219%
Phase 23114.3%
Phase 2/33114.3%
Phase 1/2114.8%

Most active sponsors

Lead sponsors with the most studies (Clayton)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC2110
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.